362 related articles for article (PubMed ID: 30825970)
1. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
[TBL] [Abstract][Full Text] [Related]
3. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
[TBL] [Abstract][Full Text] [Related]
4. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
5. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.
Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C
Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702
[TBL] [Abstract][Full Text] [Related]
6. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Barrord M; Ahmad S; Patel S; Olowokure O; Sussman J; Smith M; Poreddy S; Esslinger H; Latif T; Choe K; Kharofa J
Pancreas; 2020 Aug; 49(7):941-946. PubMed ID: 32658077
[TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
9. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
[TBL] [Abstract][Full Text] [Related]
11. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.
Comito T; Cozzi L; Clerici E; Franzese C; Tozzi A; Iftode C; Navarria P; D'Agostino G; Rimassa L; Carnaghi C; Personeni N; Tronconi MC; De Rose F; Franceschini D; Ascolese AM; Fogliata A; Tomatis S; Santoro A; Zerbi A; Scorsetti M
Technol Cancer Res Treat; 2017 Jun; 16(3):295-301. PubMed ID: 27311310
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
[TBL] [Abstract][Full Text] [Related]
15. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Huang J; Robertson JM; Ye H; Margolis J; Nadeau L; Yan D
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1120-5. PubMed ID: 22099048
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Tran NH; Sahai V; Griffith KA; Nathan H; Kaza R; Cuneo KC; Shi J; Kim E; Sonnenday CJ; Cho CS; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):124-133. PubMed ID: 31494181
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
18. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
Mahadevan A; Miksad R; Goldstein M; Sullivan R; Bullock A; Buchbinder E; Pleskow D; Sawhney M; Kent T; Vollmer C; Callery M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e615-22. PubMed ID: 21658854
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
20. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
